Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas.
Patients with objectively measurable soft tissue sarcomas, osteosarcomas, chondrosarcomas, and mesotheliomas were treated with dibromodulcitol (DBD) (180 mg/m2 p.o. days 1-10 q4 wks.). ICRF-159 (300 mg/m2 p.o. tid days 1-3 q4 wks), or maytansine (MAYT) (1.5 mg/m2 I.V. q3 wks.). Forty-five evaluable patients received DBD, 47 MAYT, and 37 ICRF-159. Only patients who had had their histopathologic diagnoses confirmed by a pathology reference panel were included in the final analysis. Two patients had objective partial responses: a patient with osteosarcoma who responded to DBD and a patient with fibrosarcoma who had a partial response of brief duration to ICRF-159. Approximately 70% of the patients treated with each drug were of ECOG performance status 0 or 1, and over half had moderate or worse toxicity. It seems unlikely that these drugs have significant therapeutic activity for common mesenchymal malignancies.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008453:Maytansine / Q000009:adverse effects / Q000627:therapeutic use*; D008654:Mesothelioma / Q000188:drug therapy; D008875:Middle Aged; D008936:Mitolactol / Q000009:adverse effects / Q000627:therapeutic use*; D012516:Osteosarcoma / Q000188:drug therapy; D010078:Oxazines / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011897:Random Allocation; D011929:Razoxane / Q000009:adverse effects / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy
D010078:Oxazines; D010879:Piperazines; D008453:Maytansine; D011929:Razoxane; D008936:Mitolactol